Insiders buy $LXRX $OPK $NBRV

Insider Purchases

Ticker

Company

Insider Title

Value Traded

AGN

Allergan Plc

COB, Pres, CEO

+$20,626

CASI

Casi Pharmaceuticals, Inc.

Dir

+$419,178

EPZM

Epizyme, Inc.

Dir

+$3,050,000

IRIX

Iridex Corp

COB, CEO

+$16,956

LXRX

Lexicon Pharmaceuticals, Inc.

Pres, CEO

+$376,337

LXRX

Lexicon Pharmaceuticals, Inc.

Dir

+$12,500

NBRV

Nabriva Therapeutics Plc

10%

+$497,889

OPK

Opko Health, Inc.

SVP, CFO

+$9,045

OPK

Opko Health, Inc.

CEO, COB, 10%

+$480,411

Get the complete lowdown in our daily pharma scoop at SeekingAlpha Marketplace

$CDXS insider sells 6mn

Codexis Inc (CDXS) 10% insider sells $6,121,500. Check out the full insider sales scoop in our daily pharma scoop at our SeekingAlpha Marketplace page.

$NBRV target raised

Wedbush Reiterates Outperform on Nabriva Therapeutics AG (NBRV) raising target from $13 to $21. SunTrust Banks Raises Target from $20 to $24. Cantor Fitzgerald Reiterates Overweight with target of $16. Leerink Swann Reiterates Outperform raising target from $20 to $22.

Check out more ratings on our SeekingAlpha Marketplace page.

$AGN unusual approach to protect IP

We discuss Allergan’s (AGN) creative legal approach to protecting its IP for its RESTASIS drug by transferring all its patents to the Saint Regis Mohawk Tribe.

Read the full discussion on our SeekingAlpha Marketplace page.

$NBRV further upside

Our daily analysis of a stock with a major event/upside: Nabriva (NBRV) stock doubled on 200x normal volume (Vol / Avg. 17.49M/74,701.00) on the back of positive results from one of two pivotal phase trials evaluating intravenous to oral lefamulin in patients with community-acquired bacterial pneumonia (CABP).

Read full post in our daily pharma scoop on our SeekingAlpha Marketplace page.

Looking at huge upside for $ACAD

Acadia (ACAD) Nuplazid looks at market potential of $10bn for PDP and $50bn for ADP. Read the complete scoop in our Daily Pharma Scoop at SeekingAlpha Marketplace.

$NEOS saw a sell-off on Friday?

Neos Therapeutics (NEOS) saw a sell-off on Friday despite getting approval for its Adzenys ER treatment for ADHD that same day.

Read our take on the news, in our Daily Pharma Scoop at SeekingAlpha Marketplace.

Marketplace research on $TSRO available

Tesaro’s (TSRO) Zejula, approved by the FDA in March, received a positive CHMP opinion in EU. We have Marketplace research on TSRO available.

Why were we neutral on $ARRY?

Array BioPharma (ARRY) has a public offering of 20,930,232 shares of common stock at $10.75 per share. Stock is currently at $10.82. ... overall we were neutral. 

Read why, in our Daily Pharma Scoop at SeekingAlpha Marketplace.

$RDUS insider purchases

Radius Health, Inc. (RDUS) insider purchases:

10% +$5,017,975
Pres, CEO +$199,608
CFO +$98,503

Check out all pharma insider purchases in our SeekingAlpha Marketplace Daily Pharma Scoop.